https://www.stocktitan.net/news/APVO/aptevo-provides-3q26-business-update-highlighting-growing-momentum-x2w3tdqhjxvr.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-provides-3q26-business-update-highlighting-growing-momentum-x2w3tdqhjxvr.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-therapeutics-announces-closing-of-existing-warrants-exercise-2x1i3elp8ixv.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-therapeutics-announces-closing-of-existing-warrants-exercise-2x1i3elp8ixv.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-therapeutics-announces-exercise-of-existing-warrants-for-3-0-0575jf5d19qt.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-therapeutics-announces-exercise-of-existing-warrants-for-3-0-0575jf5d19qt.html?utm_source=stocktitan-bluesky&utm_medium=social
www.biopharmcatalyst.com/news/2026/bi...
On November 9, 2026, Aptevo Therapeutics Inc. issued a press release announcing that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
On November 9, 2026, Aptevo Therapeutics Inc. issued a press release announcing that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
https://www.stocktitan.net/news/APVO/aptevo-presents-preclinical-data-at-sitc-2026-showing-potential-to-ydhccev53402.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-presents-preclinical-data-at-sitc-2026-showing-potential-to-ydhccev53402.html?utm_source=stocktitan-bluesky&utm_medium=social
On November 5, 2026, Aptevo Therapeutics Inc. issued a press release announcing an important clinical development milestone for mipletamig: a substantial reduction in infusion-related reactions (IRRs) following successive refinements to its priming-dose regimen.
On November 5, 2026, Aptevo Therapeutics Inc. issued a press release announcing an important clinical development milestone for mipletamig: a substantial reduction in infusion-related reactions (IRRs) following successive refinements to its priming-dose regimen.
https://www.stocktitan.net/news/APVO/aptevo-achieves-key-clinical-development-objective-significantly-iv41i7mx8x54.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-achieves-key-clinical-development-objective-significantly-iv41i7mx8x54.html?utm_source=stocktitan-bluesky&utm_medium=social
Filing of Prospectus Supplement On October 30, 2026, Aptevo Therapeutics Inc. filed with the Securities and Exchange Commission (the “SEC’) a prospectus supplement (the “Prospectus Supplement” and collectively with the Prior Prospectus (as defined below), the “Prospectus”) under the Compa...
Filing of Prospectus Supplement On October 30, 2026, Aptevo Therapeutics Inc. filed with the Securities and Exchange Commission (the “SEC’) a prospectus supplement (the “Prospectus Supplement” and collectively with the Prior Prospectus (as defined below), the “Prospectus”) under the Compa...
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-apvo-mipletamig-combination-therapy-leads-to-21-stem-cell-transplantation-rate/
#APVO #Apt#APVOe#AptevoTherapeuti
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-apvo-mipletamig-combination-therapy-leads-to-21-stem-cell-transplantation-rate/
#APVO #Apt#APVOe#AptevoTherapeuti
On October 26, 2026, Aptevo Therapeutics Inc. issued a press release announcing ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine.
On October 26, 2026, Aptevo Therapeutics Inc. issued a press release announcing ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine.
https://www.stocktitan.net/news/APVO/aptevo-reports-mipletamig-combination-therapy-enabled-21-of-z0rxkzoymu4o.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-reports-mipletamig-combination-therapy-enabled-21-of-z0rxkzoymu4o.html?utm_source=stocktitan-bluesky&utm_medium=social
On October 23, 2026, Aptevo Therapeutics Inc. entered into Amendment No. 6 to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent . The Rights Agreement pertains to those certain contingent rights to purch...
On October 23, 2026, Aptevo Therapeutics Inc. entered into Amendment No. 6 to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent . The Rights Agreement pertains to those certain contingent rights to purch...
Aptevo Therapeutics Inc. (Nasdaq: APVO) filed an 8-K announcing via press release that its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, held November 4–8, 2026, in Phoenix, Arizona.
🧵 continued ↓
Aptevo Therapeutics Inc. (Nasdaq: APVO) filed an 8-K announcing via press release that its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, held November 4–8, 2026, in Phoenix, Arizona.
🧵 continued ↓
On October 14, 2026, Aptevo Therapeutics Inc. issued a press release announcing its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
On October 14, 2026, Aptevo Therapeutics Inc. issued a press release announcing its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
https://www.stocktitan.net/news/APVO/aptevo-to-showcase-multispecific-platform-at-sitc-2026-annual-8j5uzeb4ygb5.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-to-showcase-multispecific-platform-at-sitc-2026-annual-8j5uzeb4ygb5.html?utm_source=stocktitan-bluesky&utm_medium=social
On September 24, 2026, Aptevo Therapeutics Inc. issued a press release announcing progress in its next-generation trispecific programs.
On September 24, 2026, Aptevo Therapeutics Inc. issued a press release announcing progress in its next-generation trispecific programs.
Aptevo Therapeutics announced progress in its next-generation trispecific programs, focusing on optimizing candidates for scalable manufacturing ahead of future human testing. The lead candidate, APVO451, is expected to enter IND-enabling studies in 1H...
🧵 continued ↓
Aptevo Therapeutics announced progress in its next-generation trispecific programs, focusing on optimizing candidates for scalable manufacturing ahead of future human testing. The lead candidate, APVO451, is expected to enter IND-enabling studies in 1H...
🧵 continued ↓
https://www.stocktitan.net/news/APVO/aptevo-advances-next-generation-trispecific-candidate-toward-oaz6pa1if7wb.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-advances-next-generation-trispecific-candidate-toward-oaz6pa1if7wb.html?utm_source=stocktitan-bluesky&utm_medium=social
On September 22, 2026, Aptevo Therapeutics Inc. held its Special Meeting of Stockholders , at which a quorum was present.
On September 22, 2026, Aptevo Therapeutics Inc. held its Special Meeting of Stockholders , at which a quorum was present.
Hugz & xXx
Hugz & xXx